Novel Predicted B-Cell Epitopes of PSMA for Development of Prostate Cancer Vaccine

  • Pejman Hashemzadeh
  • Vajihe Ghorbanzadeh
  • Seyede Maryam Valizadeh Otaghsara
  • Hassan DariushnejadEmail author


Prostate cancer is one of the most common cancers around the world. Vaccines are a new hope for prevention of this cancer. In the case of prostate cancer, PSMA is considered as a target for vaccine development. Here, the initial data from the computational analysis of this specific antigen of the prostate membrane to find potential B-cell epitopes are described using a new bioinformatic tools. Based on the results, 673RHVIYAPSSHNKYAGE25 is the peptide with best binding affinity. These data may be useful for the effective vaccines development.


Prostate cancer B-cell Epitope PSMA 


Compliance with Ethical Standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. Arrighi H, Guess H, Metter E, Fozard J (1990) Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 16:253–261CrossRefGoogle Scholar
  2. Brusic V, August JT, Petrovsky N (2005) Information technologies for vaccine research. Expert Rev Vaccines 4:407–417. CrossRefPubMedGoogle Scholar
  3. Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–2681PubMedGoogle Scholar
  4. Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT (2000) Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 60:3782–3789PubMedGoogle Scholar
  5. De Groot AS (2006) Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov Today 11:203–209. CrossRefPubMedGoogle Scholar
  6. De Marzo AM (2008) Interaction between dietary factors and inflammation in prostate carcinogenesis. The Johns Hopkins University School of Medicine, Baltimore, MDCrossRefGoogle Scholar
  7. Drake CG (2010) Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10:580CrossRefGoogle Scholar
  8. Gathirua-Mwangi WG, Zhang J (2014) Dietary factors and risk for advanced prostate cancer. Eur J Cancer Prev 23:96–109. CrossRefPubMedPubMedCentralGoogle Scholar
  9. Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED (2003) Prostate cancer. BioDrugs 17:131–138CrossRefGoogle Scholar
  10. Jacobson T (2007) Development and evaluation of a phage-display based vaccine against prostate cancer. Numerisk analys och datalogi, Kungliga Tekniska högskolan, StockholmGoogle Scholar
  11. Jemal A et al. (2005) Cancer statistics, 2005. CA: A Cancer J Clin 55:10–30Google Scholar
  12. Karan D, Thrasher J, Lubaroff D (2008) Prostate cancer: genes, environment, immunity and the use of immunotherapy. Prostate Cancer Prost Dis 11:230CrossRefGoogle Scholar
  13. McNeel DG, Malkovsky M (2005) Immune-based therapies for prostate cancer. Immunol Lett 96:3–9CrossRefGoogle Scholar
  14. Olson WC, Heston WD, Rajasekaran AK (2007) Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2:182–190CrossRefGoogle Scholar
  15. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ (2005) Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Prev Biomark 14:2257–2260CrossRefGoogle Scholar
  16. Ryan CJ et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. New Engl J Med 368:138–148CrossRefGoogle Scholar
  17. Saha S, Raghava GP (2006) Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins 65:40–48. CrossRefPubMedGoogle Scholar
  18. Silver DA, Pellicer I, Fair WR, Heston W, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85PubMedGoogle Scholar
  19. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71:933–938CrossRefGoogle Scholar
  20. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC (1990) Family history and the risk of prostate cancer. Prostate 17:337–347CrossRefGoogle Scholar
  21. Tran C et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787–790CrossRefGoogle Scholar
  22. Voeks DJ, Martiniello-Wilks R, Russell PJ (2002) Derivation of MPR and TRAMP models of prostate cancer and prostate cancer metastasis for evaluation of therapeutic strategies. Urol Oncol 3:111–118CrossRefGoogle Scholar
  23. Zeng H et al (2005) Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer. J Androl 26:215–221CrossRefGoogle Scholar
  24. Zhou J, Zhong Y (2004) Breast cancer immunotherapy. Cell Mol Immunol 1:247–255PubMedGoogle Scholar
  25. Zhu ZY et al (1999) PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response. Cell Res 9:271CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Medical Biotechnology, Faculty of MedicineLorestan University of Medical SciencesKhorramabadIran
  2. 2.Razi Herbal Medicines Research CenterLorestan University of Medical SciencesKhorramabadIran

Personalised recommendations